Execution drives Big Pharma’s next phase of growth

Investment capacity alone is no longer enough. Value comes from executing well – turning investment, pipelines and capital allocation into near-term growth.

10 July 2026

2 mins

by:

Jong Boo Yoo Executive Director, Capital Structure & Rating Advisory, Americas

Corporate & investment bankingCapital structure and rating advisoryCorporates

Within the global pharmaceutical industry, near-term revenue growth remains the primary driver of valuation. Companies that can deliver clear and credible growth trajectories are best positioned to capitalise on investor demand, while those facing uncertainty are seeing increasing divergence in performance.

This divergence is occurring against a more challenging backdrop. A significant patent cliff is approaching (with USD400 billion+ of revenue at risk between 2026 and 2031) as policy and pricing pressures are also intensifying, which could weigh on margins and reduce revenue visibility over the medium term.

Growth is becoming more concentrated in a narrower set of therapeutic areas, increasing competition and raising the bar for successful execution.

In response, companies are investing more, and more selectively. Continued scaling of R&D, pipeline development and new product launches is critical to sustaining growth, while targeted M&A plays an important role in accelerating growth and replenishing portfolios. The emphasis is increasingly on precision rather than scale, with a focus on smaller tuck-in transactions.

Importantly, the sector retains the financial flexibility to support these priorities. Balance sheets remain strong across investment-grade pharma, providing capacity to fund both organic and inorganic growth, with meaningful headroom remaining at current ratings.

* FY26F based on broker consensus averages

Execution is therefore the key differentiator. Companies that can consistently deliver growth while deploying capital effectively are commanding a valuation premium, reinforcing that in today’s market, strategy alone is not enough. Delivery is what drives value.